» Articles » PMID: 23629710

Structural Analysis of the Role of Pseudomonas Aeruginosa Penicillin-binding Protein 5 in β-lactam Resistance

Overview
Specialty Pharmacology
Date 2013 May 1
PMID 23629710
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Penicillin-binding protein 5 (PBP5) is one of the most abundant PBPs in Pseudomonas aeruginosa. Although its main function is that of a cell wall dd-carboxypeptidase, it possesses sufficient β-lactamase activity to contribute to the ability of P. aeruginosa to resist the antibiotic activity of the β-lactams. The study of these dual activities is important for understanding the mechanisms of antibiotic resistance by P. aeruginosa, an important human pathogen, and to the understanding of the evolution of β-lactamase activity from the PBP enzymes. We purified a soluble version of P. aeruginosa PBP5 (designated Pa sPBP5) by deletion of its C-terminal membrane anchor. Under in vitro conditions, Pa sPBP5 demonstrates both dd-carboxypeptidase and expanded-spectrum β-lactamase activities. Its crystal structure at a 2.05-Å resolution shows features closely resembling those of the class A β-lactamases, including a shortened loop spanning residues 74 to 78 near the active site and with respect to the conformations adopted by two active-site residues, Ser101 and Lys203. These features are absent in the related PBP5 of Escherichia coli. A comparison of the two Pa sPBP5 monomers in the asymmetric unit, together with molecular dynamics simulations, revealed an active-site flexibility that may explain its carbapenemase activity, a function that is absent in the E. coli PBP5 enzyme. Our functional and structural characterizations underscore the versatility of this PBP5 in contributing to the β-lactam resistance of P. aeruginosa while highlighting how broader β-lactamase activity may be encoded in the structural folds shared by the PBP and serine β-lactamase classes.

Citing Articles

Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.

Falcone M, Galfo V, Tiseo G Curr Opin Infect Dis. 2024; 37(6):594-601.

PMID: 39149832 PMC: 11556876. DOI: 10.1097/QCO.0000000000001044.


Lytic transglycosylase Slt of Pseudomonas aeruginosa as a periplasmic hub protein.

Avila-Cobian L, De Benedetti S, Hoshino H, Nguyen V, El-Araby A, Sader S Protein Sci. 2024; 33(7):e5038.

PMID: 38864725 PMC: 11168074. DOI: 10.1002/pro.5038.


Drug Discovery in the Field of β-Lactams: An Academic Perspective.

Jacobs L, Consol P, Chen Y Antibiotics (Basel). 2024; 13(1).

PMID: 38247618 PMC: 10812508. DOI: 10.3390/antibiotics13010059.


Penicillin-binding protein redundancy in enables growth during alkaline shock.

Mitchell S, Kearns D, Carlson E Appl Environ Microbiol. 2023; 90(1):e0054823.

PMID: 38126750 PMC: 10807460. DOI: 10.1128/aem.00548-23.


Resistance in : A Narrative Review of Antibiogram Interpretation and Emerging Treatments.

Giovagnorio F, De Vito A, Madeddu G, Parisi S, Geremia N Antibiotics (Basel). 2023; 12(11).

PMID: 37998823 PMC: 10669487. DOI: 10.3390/antibiotics12111621.


References
1.
Chen Y, Zhang W, Shi Q, Hesek D, Lee M, Mobashery S . Crystal structures of penicillin-binding protein 6 from Escherichia coli. J Am Chem Soc. 2009; 131(40):14345-54. PMC: 3697005. DOI: 10.1021/ja903773f. View

2.
Potluri L, de Pedro M, Young K . Escherichia coli low-molecular-weight penicillin-binding proteins help orient septal FtsZ, and their absence leads to asymmetric cell division and branching. Mol Microbiol. 2012; 84(2):203-24. PMC: 3323748. DOI: 10.1111/j.1365-2958.2012.08023.x. View

3.
Kotsakis S, Caselli E, Tzouvelekis L, Petinaki E, Prati F, Miriagou V . Interactions of oximino-substituted boronic acids and β-lactams with the CMY-2-derived extended-spectrum cephalosporinases CMY-30 and CMY-42. Antimicrob Agents Chemother. 2012; 57(2):968-76. PMC: 3553701. DOI: 10.1128/AAC.01620-12. View

4.
Page M, Heim J . Prospects for the next anti-Pseudomonas drug. Curr Opin Pharmacol. 2009; 9(5):558-65. DOI: 10.1016/j.coph.2009.08.006. View

5.
Papp-Wallace K, Senkfor B, Gatta J, Chai W, Taracila M, Shanmugasundaram V . Early insights into the interactions of different β-lactam antibiotics and β-lactamase inhibitors against soluble forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. Antimicrob Agents Chemother. 2012; 56(11):5687-92. PMC: 3486531. DOI: 10.1128/AAC.01027-12. View